Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma (NEXIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03116529
Recruitment Status : Recruiting
First Posted : April 17, 2017
Last Update Posted : October 2, 2018
Information provided by (Responsible Party):
Vincent Ng, University of Maryland

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : June 2020
  Estimated Study Completion Date : June 2022